Advertisement

Person › Details
Phil L’Huillier (Catalym GmbH)
L’Huillier, Phil (Catalym 202105– CEO before MSD Europe + Cancer Research Technology + BioFocus Discovery)
![]() |
Organisation | Catalym GmbH |
Former/major organisation | Merck (US) (MSD) (Group) | |
![]() |
Product | GDF-15 (growth-differentiation factor-15) |
Product 2 | cancer immunotherapy (immuno-oncology, I-O) | |
Record changed: 2024-07-14 |
Advertisement

More documents for Phil L’Huillier
- [1] Catalym GmbH. (7/16/24). "Press Release: Catalym Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab". Munich....
- [2] Catalym GmbH. (1/9/24). "Press Release: Catalym Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists". Mainz....
- [3] Catalym GmbH. (11/22/22). "Press Release: Catalym Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors". Oxford....
- [4] Catalym GmbH. (9/26/22). "Press Release: Catalym Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the U.S.". Munich....
- [5] Catalym GmbH. (5/4/21). "Press Release: Catalym Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer". Munich....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top